Trial · NCT00886600
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
NCT00886600, Phase 3, Completed, Merck Sharp & Dohme LLC; results first posted 2009-07-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED). Trials, record NCT00886600. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00886600
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
- NCT number
- NCT00886600
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 122 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Hypertension
- Interventions
- losartan potassium, Comparator: placebo, hydrochlorothiazide (HCTZ)
- First posted
- 2009-04-23
- Last updated
- 2015-08-27
- Results first posted
- 2009-07-14
- Limitations and caveats
- Safety has been reported in the literature.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | 24 hour period at Baseline and Week 4 | |
| Primary | Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | 24-hour period at baseline and Week 4 | |
| Secondary | Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4 | Baseline and 24-hours after morning dose at Week 4 | |
| Secondary | Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6 | Baseline and 24-hours after morning dose at Week 6 | |
| Secondary | Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6 | Baseline and 24-hours after morning dose at Week 6 |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | 24 hour period at Baseline and Week 4 | The efficacy analysis followed a per protocol approach in that only patients who completed the study according to the protocol were included in the analysis. | mm Hg | MEAN |
| PRIMARY | Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | 24-hour period at baseline and Week 4 | The efficacy analysis followed a per protocol approach in that only patients who completed the study according to the protocol were included in the analysis. | mm Hg | MEAN |
| SECONDARY | Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4 | Baseline and 24-hours after morning dose at Week 4 | The efficacy analysis followed a per protocol approach in that only patients who completed the study according to the protocol were included in the analysis. | mm Hg | MEAN |
| SECONDARY | Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6 | Baseline and 24-hours after morning dose at Week 6 | The efficacy analysis followed a per protocol approach in that only patients who completed the study according to the protocol were included in the analysis. | mm Hg | MEAN |
| SECONDARY | Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6 | Baseline and 24-hours after morning dose at Week 6 | The efficacy analysis followed a per protocol approach in that only patients who completed the study according to the protocol were included in the analysis. | mm Hg | MEAN |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Placebo / HCTZ 12.5 mg | -0.2 | Standard Deviation 4.8 | mm Hg | |
| Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Losartan 50 mg q.d. / HCTZ 12.5 mg | -5.2 | Standard Deviation 5.1 | mm Hg | |
| Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Losartan 100 mg q.d. / HCTZ 12.5 mg | -6.4 | Standard Deviation 5.5 | mm Hg | |
| Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | -8.5 | Standard Deviation 6.7 | mm Hg | |
| Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Placebo / HCTZ 12.5 mg | 0 | Standard Deviation 7.8 | mm Hg | |
| Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Losartan 50 mg q.d. / HCTZ 12.5 mg | -9.2 | Standard Deviation 9.9 | mm Hg | |
| Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Losartan 100 mg q.d. / HCTZ 12.5 mg | -9.9 | Standard Deviation 7.6 | mm Hg | |
| Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | -13.2 | Standard Deviation 10.6 | mm Hg | |
| Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4 | Placebo / HCTZ 12.5 mg | -2.1 | Standard Deviation 6.9 | mm Hg | |
| Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4 | Losartan 50 mg q.d. / HCTZ 12.5 mg | -6.7 | Standard Deviation 7.8 | mm Hg |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Monotherapy | STARTED | Placebo / HCTZ 12.5 mg | 32 | |
| Double-blind Monotherapy | STARTED | Losartan 50 mg q.d. / HCTZ 12.5 mg | 29 | |
| Double-blind Monotherapy | STARTED | Losartan 100 mg q.d. / HCTZ 12.5 mg | 30 | |
| Double-blind Monotherapy | STARTED | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | 31 | |
| Double-blind Monotherapy | COMPLETED | Placebo / HCTZ 12.5 mg | 30 | |
| Double-blind Monotherapy | COMPLETED | Losartan 50 mg q.d. / HCTZ 12.5 mg | 28 | |
| Double-blind Monotherapy | COMPLETED | Losartan 100 mg q.d. / HCTZ 12.5 mg | 29 | |
| Double-blind Monotherapy | COMPLETED | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | 29 | |
| Double-blind Monotherapy | NOT COMPLETED | Placebo / HCTZ 12.5 mg | 2 | |
| Double-blind Monotherapy | NOT COMPLETED | Losartan 50 mg q.d. / HCTZ 12.5 mg | 1 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 7848024 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00886600
GET https://conductscience.org/api/trials/v1/NCT00886600/flow?page=2